Drugs / rMenB+OMV NZ
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06113198 | Nov 2023 → Sep 2026 overdue | meningococcal meningitis | GlaxoSmithKline | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rMenB+OMV NZ | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06113198 ↗ |
| Modality | Vaccine | “rMenB+OMV NZ vaccine” NCT06113198 ↗ |
| Route | Intramuscular | “administered intramuscularly” NCT06113198 ↗ |